Furthermore, this observation resonates with the superior efficacy of PPARγ agonist pioglitazone over sulfonylureas and metformin in patients with a distinct subset of diabetes characterized by severe insulin‐resistant diabetes.13 The gene discussed is PPARG; the disease is diabetes mellitus.